JOP20240028A1 - جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامة - Google Patents
جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامةInfo
- Publication number
- JOP20240028A1 JOP20240028A1 JOJO/P/2024/0028A JOP20240028A JOP20240028A1 JO P20240028 A1 JOP20240028 A1 JO P20240028A1 JO P20240028 A JOP20240028 A JO P20240028A JO P20240028 A1 JOP20240028 A1 JO P20240028A1
- Authority
- JO
- Jordan
- Prior art keywords
- immune responses
- liposomes containing
- phosphorylated tau
- tau peptides
- containing phosphorylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163260227P | 2021-08-12 | 2021-08-12 | |
| US202163263541P | 2021-11-04 | 2021-11-04 | |
| US202263267975P | 2022-02-14 | 2022-02-14 | |
| PCT/US2022/074902 WO2023019241A2 (en) | 2021-08-12 | 2022-08-12 | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240028A1 true JOP20240028A1 (ar) | 2024-02-12 |
Family
ID=85201019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0028A JOP20240028A1 (ar) | 2021-08-12 | 2024-02-12 | جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامة |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20250134973A1 (https=) |
| EP (1) | EP4384216A4 (https=) |
| JP (1) | JP2024532787A (https=) |
| KR (1) | KR20240042508A (https=) |
| AU (1) | AU2022328342A1 (https=) |
| CA (1) | CA3228878A1 (https=) |
| CL (1) | CL2024000408A1 (https=) |
| IL (1) | IL310761A (https=) |
| JO (1) | JOP20240028A1 (https=) |
| MX (1) | MX2024001906A (https=) |
| WO (1) | WO2023019241A2 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3239368A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| KR102710762B1 (ko) * | 2017-10-25 | 2024-09-25 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
| AU2020219804A1 (en) * | 2019-02-08 | 2021-08-19 | Ac Immune S.A. | Method of safe administration of phosphorylated Tau peptide vaccine |
| EA202192891A1 (ru) * | 2019-04-24 | 2022-02-04 | Янссен Фармасьютикалз, Инк. | Гетерологичное введение анти-тау вакцин |
-
2022
- 2022-08-12 JP JP2024508568A patent/JP2024532787A/ja active Pending
- 2022-08-12 KR KR1020247007914A patent/KR20240042508A/ko active Pending
- 2022-08-12 AU AU2022328342A patent/AU2022328342A1/en active Pending
- 2022-08-12 WO PCT/US2022/074902 patent/WO2023019241A2/en not_active Ceased
- 2022-08-12 MX MX2024001906A patent/MX2024001906A/es unknown
- 2022-08-12 US US18/683,001 patent/US20250134973A1/en active Pending
- 2022-08-12 IL IL310761A patent/IL310761A/en unknown
- 2022-08-12 EP EP22856833.3A patent/EP4384216A4/en active Pending
- 2022-08-12 CA CA3228878A patent/CA3228878A1/en active Pending
-
2023
- 2023-06-28 US US18/343,349 patent/US20230338535A1/en not_active Abandoned
-
2024
- 2024-02-09 CL CL2024000408A patent/CL2024000408A1/es unknown
- 2024-02-12 JO JOJO/P/2024/0028A patent/JOP20240028A1/ar unknown
-
2025
- 2025-01-06 US US19/010,408 patent/US20250144212A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4384216A4 (en) | 2025-08-20 |
| US20250134973A1 (en) | 2025-05-01 |
| WO2023019241A3 (en) | 2023-03-23 |
| AU2022328342A1 (en) | 2024-02-22 |
| IL310761A (en) | 2024-04-01 |
| US20250144212A1 (en) | 2025-05-08 |
| KR20240042508A (ko) | 2024-04-02 |
| EP4384216A2 (en) | 2024-06-19 |
| CA3228878A1 (en) | 2023-02-16 |
| WO2023019241A2 (en) | 2023-02-16 |
| US20230338535A1 (en) | 2023-10-26 |
| CL2024000408A1 (es) | 2024-08-23 |
| MX2024001906A (es) | 2024-05-16 |
| JP2024532787A (ja) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
| GT200600033A (es) | Formulaciones liquidas estabilizadas de polipeptido | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| CR20210318A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| MX2021012032A (es) | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| JOP20240028A1 (ar) | جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامة | |
| UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
| CL2023000004A1 (es) | Formulación en concentración alta de proteínas de unión a antígeno del factor xii | |
| JOP20240024A1 (ar) | صياغات الأجسام المضادة | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| MX2021012782A (es) | El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion. | |
| CO2023014918A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3 | |
| CO2026000834A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-bcma x anti-cd3 | |
| CL2022003586A1 (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas | |
| WO2024031049A3 (en) | Pharmaceutical compositions of fusion proteins and methods of use thereof | |
| GEP20257801B (en) | Formulations |